Indivior Ordinary Shares (NASDAQ: INDV) — Perfil da empresa, notícias e dados financeiros
Indivior develops medications aimed at treating addiction and serious mental illnesses, focusing on innovative solutions.
Indivior Ordinary Shares
Indivior (LSE:INDV), (NASDAQ:INDV) is a pharmaceutical company focused on developing medications to treat addiction and serious mental illnesses. Their work is centered around providing innovative solutions to individuals suffering from opioid dependence, alcohol dependence, and schizophrenia, among other conditions. Their portfolio includes both marketed therapies and a pipeline of products at various stages of development, aimed at addressing unmet medical needs within these therapeutic areas. Indivior operates with the mission to transform addiction from a global human crisis to a recognized and treated chronic disease, striving to expand access to treatment and to support patients in reclaiming their lives. Their commitment to patient-centric healthcare is evident in their ongoing research and development efforts, as well as their educational and support initiatives for patients and healthcare providers.
Resumo
Operações
Produtos e/ou serviços de Indivior Ordinary Shares
- Addiction Treatment Drugs: Indivior develops, manufactures, and commercializes medications for treating opioid dependence and alcohol dependence. Their most well-known product is Suboxone, a medication used to manage opioid dependence.
- Clinical Trials: They conduct clinical trials to evaluate the safety and efficacy of their drug candidates in various stages of development.
- Regulatory Affairs: They work with regulatory agencies to obtain marketing approval for their drugs, allowing them to be prescribed to patients.
- Partnerships and Collaborations: Indivior may collaborate with other pharmaceutical companies or research institutions to leverage expertise and resources for broader development and commercialization of their drugs.
- Manufacturing and Supply Chain: While not directly involved in large-scale manufacturing, they partner with other companies to ensure the quality and supply of their drugs if they reach the market.
- Access and Affordability Programs: Indivior may implement programs to improve access and affordability of their medications for patients, particularly those in underserved communities.
equipe executiva do Indivior Ordinary Shares
- Joseph J. CiaffoniCEO & Director
- Ryan PreblickChief Financial Officer
- Christian HeidbrederChief Scientific Officer
- Jeffrey W. BurrisChief Legal Officer
- Patrick a. BarryChief Commercial Officer
- Jason ThompsonVice President of Investor Relations
- Kevin L. EspinozaChief Integrity & Compliance Officer
- Angela Colon-MahoneyChief Human Resources Officer
- Vanessa ProcterExecutive Vice President of Corporate Affairs
- Ann WheelerChief Medical Officer
Histórico de dividendos
Dividendos por ação pagos pela Indivior Ordinary Shares, por ano fiscal.
| Ano fiscal | Intermediário | Final | Especial | Total |
|---|---|---|---|---|
| FY2026(até o momento) | — | — | — | $16.2600 |
| FY2016 | — | — | — | $0.4750 |
| FY2015 | — | — | — | $0.1600 |
Principais indicadores financeiros
Resultados divulgados pela Indivior Ordinary Shares, em USD.
- Cap. de mercado
- 4,1 bi
- Receita (TTM)
- 1,3 bi
- P/L
- 12.4
- LPA (diluído, TTM)
- 2.8
- Dividend yield
- —
- Margem de lucro
- 26.8%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 1,2 bi | 265 mi | 210 mi | |
| 1,2 bi | 32 mi | 2 mi | |
| 1,1 bi | -156 mi | -129 mi | |
| 901 mi | -81 mi | -44 mi |